Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Castle Biosciences Inc maintains a gross margin of 76.33%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4.40%, while the net margin is -2.68%. These profitability ratios, combined with a Return on Equity (ROE) of -5.21%, provide a clear picture of how effectively CSTL converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CSTL competes directly with industry leaders such as IART and INMD. With a market capitalization of $832.18M, it holds a significant position in the sector. When comparing efficiency, CSTL's gross margin of 76.33% stands against IART's 57.02% and INMD's 78.28%. Such benchmarking helps identify whether Castle Biosciences Inc is trading at a premium or discount relative to its financial performance.
